Board of Directors

The principal duty of the Board is to represent and protect the interests of the Company's shareholders by ensuring that the Company is well-managed in the interests of its shareholders. In doing so, the Board has the legal responsibility for overseeing the affairs of the Company. The Board's oversight function is exercised through the nomination, election and appointment of competent directors.

The Board remains responsible for oversight and has an obligation to keep informed in order to assist Management in formulating, developing and implementing plans and serves as a body to review and provide advice to Management on the operations of the Company. These duties are discharged by the full Board, the Board's Committees and by individual members of the Board, as may be appropriate relative to the circumstance.

Additional information on Board composition, committees, processes, information and functions can be found in the 2010 Annual Report and Accounts in the Financial Information section and also in the Corporate Governance section.

• (A) = Audit
• (N) = Nomination
• (R) = Remuneration
  

Roy Davis, Chief Executive Officer

Roy Davis joined the Company as Chief Executive Officer with effect from 17 November 2008 with over 25 years of operational line management and strategic consulting experience. Mr Davis was Chief Executive Officer of Gyrus Group plc, a quoted leading medical device company, from June 2007, before it was acquired by the Olympus Corporation of Japan in February 2008. Before becoming CEO he served as Chief Operating Officer of the company from 2003. Mr Davis joined Gyrus as a Non-executive Director at the time of its flotation in 1997. He was previously CEO of NTERA, a nanotechnology company and before that spent almost 10 years with Arthur D Little, the global management consulting company, where he was Vice President and Global Head of its operations management business. Mr Davis has also held senior operational positions for Tricom, Reuters and Molex in the US, Taiwan and Europe. Mr Davis holds a mechanical engineering degree and obtained an MBA from the London Business School.

Christine Soden, Chief Financial Officer

Christine Soden joined Optos as Chief Financial Officer in September 2009 and was appointed to the
Board on 1 December 2009. She joined Optos from BTG plc, the FTSE 250 specialty pharmaceuticals company where she became Chief Financial Officer in 2005. Following the acquisition of Protherics plc in December 2005, Christine became Chief Operating Officer of BTG and helped integrate the two businesses. Prior to BTG, between 2000 and 2005, Christine was Chief Financial Officer at Oxagen Limited, a privately owned drug discovery company and from 1996 until 1999, Christine was Finance Director of Chiroscience Group plc before becoming Chief Financial Officer of Celltech Chiroscience plc following the merger of the two companies. Prior to this, Christine spent over four years as Group Financial Controller of Medeva plc. She has a degree in mathematics from Durham University and is a Chartered Accountant.

Dr. Peter Fellner, Non-Executive Chairman (A•R•N)

Dr Fellner joined the Company as Chairman with effect from 1 January 2010. Previously, Dr Fellner served as CEO of Celltech Group Plc from 1990 to 2003, and oversaw its growth from an early-stage R&D company, valued at about £50m, into the UK’s largest biotechnology company, a constituent of the FTSE 100 index, and also listed on the NYSE. He then served as its Chairman from 2003 until its acquisition for £1.53 billion in 2004. Dr Fellner joined Celltech from Roche UK, where he served as CEO from 1986 to 1990, having previously been Director of the Roche Research Centre in the UK. Dr Fellner currently serves as Chairman of the medical technology company Consort Medical Plc, and of the biotechnology companies Vernalis Plc, Astex Therapeutics Ltd and Biotie Therapies Corp. He is also a Director of the global biopharmaceutical company UCB SA, and of the European bioscience company Evotec AG. Recently he also served as Chairman of the biotechnology company Acambis Plc, and of Premier Research Group Plc, a CRO, until they were each acquired during 2008.

John Goddard, FCA, Non-Executive Director (A•N)

Mr. John Goddard FCA joined the company as a Non-executive Director in June 2011.  Mr. Goddard has had a distinguished career in the global pharmaceuticals industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning. He has extensive experience of mergers and acquisitions, and had significant involvement in the merger of Astra and Zeneca. Prior to his retirement from AstraZeneca last year, Mr. Goddard was responsible for building a 100-strong global team focused upon M&A and licensing, which completed 75 transactions in four years, including several acquisitions, in-licensing and out-licensing of compounds, and disposals. Latterly, Mr. Goddard became Chairman of the AstraZeneca spin-out, Aptium Oncology, and of the substantial medical device business, Astratech. Mr. Goddard is a Member of the Board of Directors of Intas Pharmaceuticals Ltd and Renovo Group plc and serves on the Advisory Board of DRI Capital Inc.

Dr. Peter H. Kehoe, Non-Executive Director (R•N)

Dr Kehoe joined the Company as a Non-executive Director in October 2010. Since 1984, Dr Kehoe has been a principal of Kehoe Eye Care, PC in Galesburg, Illinois, USA. From 1997 to 1998 Dr Kehoe served as President of the Illinois Optometric Association and received their Optometrist of the Year Award in 2001. He served on the Board of Trustees of the American Optometric Association from 1999 to 2010 and as President of the 36,000 member organisation in 2008 to 2009. During his AOA tenure, he co-ordinated the optometric infant and children’s vision coalition and was instrumental in the 2005 launch of InfantSEE®, a public health programme offering comprehensive no-cost eye examinations for any child in America in their first year of life. Dr Kehoe serves as a North American representative on the Governing Board of the World Council of Optometry. In 2010, he was named as a consultant to Transitions Optical serving as a Professional Relations Adviser. Dr Kehoe holds an OD degree and a Doctor of Science from the Illinois College of Optometry, Chicago. He became a Fellow in the American Academy of Optometry in 1999 and is an Active Candidate of the American Board of Optometry.

Barry M. Rose, Non-Executive Director (A•R•N)

Barry M Rose joined the Company as a Non-executive Director in December 2005 and serves as the Senior Independent Director to the Board and as Chairman of the Audit Committee. Mr Rose was Chief Executive of Scottish Provident UK from 1993 to 2001. He is Chairman of Baillie Gifford Shin Nippon plc. Mr Rose is also a Non-executive Director of Wolfson Microelectronics plc, Shires Smaller Companies plc, and Dimensional Imaging Ltd. Mr Rose has an Honours degree in Mathematics from Manchester University.

David Wilson, Non-Executive Director (R•N)

Mr. David Wilson joined the company as a Non-executive Director in June 2011.  Mr. Wilson has 26 years of experience in the City and is currently Deputy Chief Executive of the Investment Banking business at Matrix Group. Until February this year he was the Chief Executive of Piper Jaffray Ltd., a position he held from 2005. Mr. Wilson helped launch the firm’s investment banking and M&A advisory service in Europe, which became a market-leading healthcare franchise. He was appointed to the Operating Board of Piper Jaffray & Co., the US-based parent company, in 2008 and as Chairman of the firm’s Global Healthcare Group in 2010. He has extensive global fundraising and cross-border M&A experience. Previous positions include Joint Head of UK Investment Banking at ING Barings, Director of Investment Banking at Deutsche Bank and Head of Small Companies Corporate Broking at UBS.

Rosalyn S. Wilton, Non-Executive Director (A•R•N)

Rosalyn Wilton joined the Company as a Non-executive Director in August 2007 and serves as Chairman of the Remuneration Committee. Mrs Wilton stepped down in October 2009 as Chairman of Ipreo Holdings LLC, the US-based financial data and solutions group which was formed following the merger of i-Deal LLC and Hemscott Group Ltd. Before the merger, Mrs Wilton was Chief Executive Officer of Hemscott plc. Mrs Wilton has previously served as Managing Director of Reuters Information Services and Reuters Transactions Products and was a member of the Reuters Executive Committee. Mrs Wilton has held non-executive directorship positions with Scottish Widows and the London International Financial Futures Exchange. Mrs Wilton serves as a Senior Adviser to 3i Investments. Mrs Wilton holds a BSc (Hons) from the University of London.